Tear Sheet

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Tear Sheet

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction, multiple sclerosis and oncology. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

Press Releases
Date Title
01/08/20 Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference
12/12/19 Alkermes Media Statement Regarding FDA Warning Letter
11/26/19 Alkermes to Present at the Evercore ISI 2nd Annual HealthCONx Conference
11/25/19 Alkermes Completes Acquisition of Rodin Therapeutics
11/19/19 Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder
Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

SEC Filings

Filing date Description

Report of unscheduled material events or corporate event

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

CT ORDER

Report of unscheduled material events or corporate event